{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kwon J"],"funding":["National Institute of Allergy and Infectious Diseases","NIAID NIH HHS","National Institutes of Health","NIH HHS"],"pagination":["141-147"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11259209"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["79(1)"],"pubmed_abstract":["<h4>Background</h4>Equitable representation of members from historically marginalized groups is important in clinical trials, which inform standards of care. The goal of this study was to characterize the demographics and proportional subgroup reporting and representation of participants enrolled in randomized controlled trials (RCTs) of antibacterials used to treat Staphylococcus aureus infections.<h4>Methods</h4>We examined randomized controlled registrational and strategy trials published from 2000 to 2021 to determine the sex, race, and ethnicity of participants. Participant to incidence ratios (PIRs) were calculated by dividing the percentage of study participants in each demographic group by the percentage of the disease population in each group. Underrepresentation was defined as a "],"journal":["Clinical infectious diseases : an official publication of the Infectious Diseases Society of America"],"pubmed_title":["Participant Diversity in United States Randomized Controlled Trials of Antibacterials for Staphylococcus aureus Infections, 2000-2021."],"pmcid":["PMC11259209"],"funding_grant_id":["UM1 AI104681","UM1AI104681"],"pubmed_authors":["Ledbetter L","Ruffin F","Knisely JM","Kwon J","Bizzell E","Pelletiers W","Galloway Pena J","van Duin D","Fowler VG","Pettigrew MM","Baum K","Chambers HF"],"additional_accession":[]},"is_claimable":false,"name":"Participant Diversity in United States Randomized Controlled Trials of Antibacterials for Staphylococcus aureus Infections, 2000-2021.","description":"<h4>Background</h4>Equitable representation of members from historically marginalized groups is important in clinical trials, which inform standards of care. The goal of this study was to characterize the demographics and proportional subgroup reporting and representation of participants enrolled in randomized controlled trials (RCTs) of antibacterials used to treat Staphylococcus aureus infections.<h4>Methods</h4>We examined randomized controlled registrational and strategy trials published from 2000 to 2021 to determine the sex, race, and ethnicity of participants. Participant to incidence ratios (PIRs) were calculated by dividing the percentage of study participants in each demographic group by the percentage of the disease population in each group. Underrepresentation was defined as a ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2025-04-03T23:22:59.721Z","creation":"2025-04-03T23:22:59.721Z"},"accession":"S-EPMC11259209","cross_references":{"pubmed":["38306502"],"doi":["10.1093/cid/ciae049"]}}